ERBB2 and breast cancer: Clinical trials using Tocilizumab in combination with other monoclonal antibodies, chemotherapies, and immunotherapies to treat cancers such as HER2+ breast cancer, B-cell Non-Hodgkin Lymphoma, metastatic NSCLC, and recurrent metastatic colorectal adenocarcinoma are ongoing [284].